PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
799.80%
Cash & equivalents growing 799.80% while AGEN's declined -14.21%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
799.80%
Below half of AGEN's -14.21%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
700.88%
≥ 1.5x AGEN's 1.93%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-9.67%
Below half AGEN's 2.36%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.93%
Below half of AGEN's 4.84%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
569.03%
≥ 1.5x AGEN's 3.18%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
1.26%
Less than half of AGEN's 40.31%. David Dodd sees a more disciplined AP approach or lower volume.
-42.54%
Less than half of AGEN's 137.15%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
5.04%
0.5-0.75x AGEN's 9.10%. Martin Whitman sees weaker advanced billings vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.15%
Less than half of AGEN's 11.72%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.72%
Less than half of AGEN's 5.59%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-2.99%
Less than half of AGEN's 7.63%. David Dodd sees far fewer liability expansions relative to competitor.
-92.57%
Less than half of AGEN's 4.96%. David Dodd sees fewer share issuances vs. competitor.
-2.16%
0.5-0.75x AGEN's -3.57%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1581.26%
Below half AGEN's -11.59%. Michael Burry sees potential underperformance in building shareholder capital.
569.03%
≥ 1.5x AGEN's 3.18%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-16.19%
Less than half of AGEN's 26.73%. David Dodd sees less overall debt expansion vs. competitor.
-1028.99%
Less than half of AGEN's 33.40%. David Dodd sees better deleveraging or stronger cash buildup than competitor.